Digital Edition
Ophthalmology Times: March/April 2026
Volume: 51
Issue: 2
Ophthalmology Times: January/February 2026
Volume: 51
Issue: 1
Ophthalmology Times: November/December 2025
Volume: 50
Issue: 6
Ophthalmology Times: September/October 2025
Volume: 50
Issue: 5
Ophthalmology Times: July/August 2025
Volume: 50
Issue: 4
Ophthalmology Times: May/June 2025
Volume: 50
Issue: 3
Ophthalmology Times: March/April 2025
Volume: 50
Issue: 2
Ophthalmology Times: January/February 2025
Volume: 50
Issue: 1
Ophthalmology Times: December 2024
Volume: 49
Issue: 12
Ophthalmology Times: November 2024
Volume: 49
Issue: 11
Ophthalmology Times: October 2024
Volume: 49
Issue: 10
Ophthalmology Times: September 2024
Volume: 49
Issue: 9
Ophthalmology Times: August 2024
Volume: 49
Issue: 8
Ophthalmology Times: July 2024
Volume: 49
Issue: 7
Ophthalmology Times: June 2024
Volume: 49
Issue: 6
Ophthalmology Times: May 2024
Volume: 49
Issue: 5
Ophthalmology Times: April 2024
Volume: 49
Issue: 4
Ophthalmology Times: March 2024
Volume: 49
Issue: 3
Ophthalmology Times: February 2024
Volume: 49
Issue: 2
Ophthalmology Times: January 2024
Volume: 49
Issue: 1
Ophthalmology Times: December 2023
Volume: 48
Issue: 12
Ophthalmology Times: November 2023
Volume: 48
Issue: 11
Ophthalmology Times: October 2023
Volume: 48
Issue: 10
Ophthalmology Times: September 2023
Volume: 48
Issue: 9
Ophthalmology Times: August 2023
Volume: 48
Issue: 8
Ophthalmology Times: July 2023
Volume: 48
Issue: 7
Ophthalmology Times: June 2023
Volume: 48
Issue: 6
Ophthalmology Times: May 2023
Volume: 48
Issue: 5
Ophthalmology Times: April 2023
Volume: 48
Issue: 4
Ophthalmology Times: March 2023
Volume: 48
Issue: 3
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
5